These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 10495907)

  • 21. Plasma von Willebrand factor changes during various reproductive cycle stages in mixed-breed dogs with normal von Willebrand factor and in Doberman pinschers with type-I von Willebrand's disease.
    Moser J; Meyers KM; Russon RH; Reeves JJ
    Am J Vet Res; 1998 Jan; 59(1):111-8. PubMed ID: 9442254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DDAVP in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    Blood; 1986 Feb; 67(2):465-8. PubMed ID: 3080040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor.
    Rodeghiero F; Castaman G; Di Bona E; Ruggeri M; Lombardi R; Mannucci PM
    Eur J Haematol; 1988 Feb; 40(2):163-7. PubMed ID: 3126081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease.
    Casonato A; Pontara E; Dannhaeuser D; Bertomoro A; Sartori MT; Zerbinati P; Girolami A
    Blood Coagul Fibrinolysis; 1994 Dec; 5(6):959-64. PubMed ID: 7893933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma von Willebrand factor antigen concentration as a predictor of von Willebrand's disease status in German Wirehaired Pointers.
    Brooks M; Raymond S; Catalfamo J
    J Am Vet Med Assoc; 1996 Sep; 209(5):930-3. PubMed ID: 8790543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).
    Olsen EH; McCain AS; Merricks EP; Fischer TH; Dillon IM; Raymer RA; Bellinger DA; Fahs SA; Montgomery RR; Keith JC; Schaub RG; Nichols TC
    Blood; 2003 Jul; 102(2):436-41. PubMed ID: 12649145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
    Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
    Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Collagen-binding of von Willebrand's factor antigen in the classification of von Willebrand's disease.
    Duggan MJ; DiMichele DM; Christian MJ; Fink LM; Hathaway WE
    Am J Clin Pathol; 1987 Jul; 88(1):97-102. PubMed ID: 3496781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers.
    Casonato A; Pontara E; Bertomoro A; Zucchetto S; Zerbinati P; Girolami A
    J Lab Clin Med; 1997 Feb; 129(2):251-9. PubMed ID: 9016863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T
    Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
    Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
    Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.